Figure - available via license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Content may be subject to copyright.
Figure. Binding of AMP1 (turquoise) to the N-terminal domain of the p24 antigen (green).
Similar publications
Short histidine-rich peptides could serve as novel activatable vectors for delivering cytotoxic payloads to tumor and neovasculature cells. This explorative study reports preliminary results showing that zinc ions, which are found in elevated levels at neovasculature sites, can trigger the intracellular delivery of a short antimicrobial peptide whe...
• The rise in antimicrobial resistance is widely acknowledged as a result of misuse and overuse of livestock antibiotics. Once transferred to human beings, these strains can cause diseases that are not treatable by antibiotics. • Antibiotics can largely accumulate in the environment through livestock excretion and eventually threaten public health....
Background
The problem of increasing resistance against conventional antibiotics has drawn people’s attention. Therefore, the development of novel antibacterial agents with effective and safe therapeutic effects is imminent. Antimicrobial peptides (AMPs) are considered a promising class of antibacterial agents due to their broad antibacterial spect...
Antimicrobial peptides (AMPs) are classically known as important effector molecules in innate immunity across all multicellular organisms. However, emerging evidence begins to suggest multifunctional properties of AMPs beyond their antimicrobial activity, surprisingly including their roles in regulating neuronal function, such as sleep and memory f...
Hospital‐acquired infection causes many deaths worldwide and calls for the urgent need for antibacterial biomaterials used in clinic that can selectively kill harmful bacteria. The present study rationally designs fusion peptides capable of undergoing 2D self‐assembly on the poly(methyl methacrylate) surface to form a smart surface, which can maint...
Citations
Development of a serotyping‐capable dengue detection test is hampered by the absence of an identified unique marker that can detect specific dengue virus (DENV) serotype. In the current commercially available antibody‐capture diagnostic methods, immobilized non‐structural 1 (NS1) antigen indiscriminately binds and detects immunoglobulin M (IgM) or immunoglobulin G (IgG) against any serotype thus limiting its capability to distinguish existing serotypes of dengue. Identification of dengue serotype is important because certain serotypes are associated with severe forms of dengue as well as dengue hemorrhagic fever (DHF). In this study, we aimed to identify an immunogenic epitope unique to DENV2 NS1 antigen and determine the binding specificity of its synthetic peptide mimotope to antibodies raised in animal models. Selection of a putative B‐cell epitope from the reported DENV2 NS1 antigen was done using Kolaskar & Tongaonkar Antigenicity Prediction, Emini Surface Accessibility Prediction and Parker Hydrophilicity Prediction available at the Immune Epitope Database and Analysis Resource (IEDB). Uniqueness of the B‐cell epitope to DENV2 was analyzed by BLASTp. Immunogenicity of the synthetic peptide analog of the predicted immunogenic epitope was tested in rabbits. The binding specificity of the antibodies raised in animals and the synthetic peptide mimotope was tested by indirect enzyme‐linked immunosorbent assay (ELISA). A synthetic peptide analog comprising the unique epitope of DENV2 located at the 170th – 183rd position of DENV2 NS1 was found to be immunogenic in animal models. The antipeptide antibody produced in rabbits showed specific binding to the synthetic peptide mimotope of the predicted unique DENV2 NS1 immunogenic epitope. This article is protected by copyright. All rights reserved.
